Multiple Sclerosis

Amyotrophic Lateral Sclerosis

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis by Mora JS, et al. in Ther Adv Neurol Disord (2021)

The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS by Kovacs M, et al. in Acta Neuropathol Commun (2021). []

Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A mice by Harrison JM et al. Neurobiol Dis (2020).

Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis by Trias E et al. in Glia (2020).

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial by Mora JS et al. in Amyotroph Lateral Scler Frontotemporal Degener (2019).

Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS by Trias E et al. in JCI Insight (2018).

Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS by Trias E et al. in JCI Insight (2018).

ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? by Petrov D et al. in Front Aging Neurosci (2017).

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis by Trias E et al. in J Neuroinflammation (2017).

Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient by Salvado M et al. in World J Gastroenterol (2016).

Alzheimer’s Disease

Masitinib in mild to moderate Alzheimer’s disease: Results from study AB09004 by Bruno Dubois, et al. in Alzheimer’s & Dementia: Journal of the Alzheimer’s Association (2021).

Effects of chronic masitinib treatment in APPswe/PSEN1dE9 transgenic mice modeling Alzheimer’s disease by Li T et al. in J Alzheimers Dis (2020).

Masitinib for the treatment of mild to moderate Alzheimer’s disease by Folch J et al. in Expert Rev Neurother (2015).

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomized, placebo-controlled phase 2 trial by Piette F et al. in Alzheimers Res Ther (2011).



Pancreatic Cancer

Prostate Cancer



Effects of tyrosine kinase inhibitor-masitinib mesylate on canine mammary tumour cell lines by Ustun-Alkan F, et al. in J Vet Res (2021).

Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010-2019) by Kuijlaars M, et al. in J Small Anim Pract (2021).

Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats by Leong ZP et al. in Vascul Pharmacol (2020).

Piperazining’ the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib by Aljoundi AK et al. in Future Med Chem (2019).

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats by Belin-Rauscent A et al. in Psychopharmacology (2018).

The cKit Inhibitor, Masitinib, Prevents Diabetes-Induced Retinal Vascular Leakage by Kim SR et al. in Invest Ophthalmol Vis Sci (2016).

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report by Prosvicova J et al. in Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2016).

Local release of masitinib alters in vivo implantable continuous glucose sensor performance by Avula M et al. in Biosens Bioelectron (2015).

Neuroprotective effect of masitinib in rats with postischemic stroke by Kocic I et al. in Naunyn Schmiedebergs Arch Pharmacol (2015). []

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance by Kathawala RJ et al. in Int J Oncol (2014).

Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study by Kathawala RJ et al. in Mol Cancer Ther (2014).

Modulation of the foreign body response to implanted sensor models through device-based delivery of the tyrosine kinase inhibitor, masitinib by Avula MN et al. in Biomaterials (2014).

Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein by Zandvliet M et al. in J Vet Pharmacol Ther (2013).

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT by Dubreuil P et al. in PLoS One (2009).